Choice of anti-epileptic drugs for glioma associated seizure

International Conference on Epilepsy & Treatment

September 21-22, 2015 Baltimore, USA

Mao Qing and Yang Yuan

Si Chuan University, China

Posters-Accepted Abstracts: J Neurol Disord

Abstract :

Glioma is the most frequent and deadliest primary malignant brain neoplasm in humans and accounts for more than 40% of all adult brain tumors. Although gross-total resection is an effective control measure for glioma-related epileptic activity approximately 30% of glioma patients with a history of preoperative seizures do not achieve satisfactory seizure prognoses which significantly affects the glioma patients� quality of life and makes it difficult for these patients to return to work and society. Surprisingly, at present, there are no specific GAS guidelines to aid neurosurgeons in prescribing Anti-Epileptic Drugs (ADEs) for post-surgery glioma patients; instead, the choice of prescriptions is based on the neurosurgeons� personal preferences and clinical experiences. We did a series of meta-analysis on the choice of AEDs for glioma patients; their efficiency and impact on the overall survival for glioma patients. Phenytoin, carbamazepine, sodium valproate and levetiracetam are the most frequently used AEDs in clinical settings for the treatment or prevention of seizure activity in post-surgery glioma patients. We found that no significant difference between the efficacies of P450 enzyme-inducing and non-enzyme-inducing anti-epileptic drugs for prophylactic late seizure treatment was observed, however, valproic acid used in adult glioblastoma multiform could prolong the patients� survival and we found that levetiracetam is an efficient ADE for glioma associated seizure.

Biography :

Email: qingmao2000@163.com